Definium's Phase 3 LSD Depression Data Stuns the Tape as AbbVie Spends $10.9 Billion on Apogee

Definium Therapeutics (NASDAQ:DFTX) reported Q2 results and discussed Phase II GAD data for DT120, saying efficacy was seen by week one and remained significant through week 12, with improvements on secondary endpoints and favorable tolerability. It said VOYAGE and PANORAMA were re-estimated to exceed 99% power. Net loss was $159M, including $86.2M non-cash warrant fair-value expense. The company raised about $758M net in June and had about $1.1B cash to fund operations into 2030.

Definium Therapeutics (NASDAQ: DFTX) reported Q2 2026 results and Phase 3 updates for DT120 ODT. It said Phase 3 Emerge in major depressive disorder met primary and key secondary endpoints, with placebo-adjusted MADRS improvements of 8.1 points at Week 6 and 7.3 at Week 12. Voyage and Panorama topline data are expected Aug 10 and Sept 2026. Cash, cash equivalents and investments were about $1.1B as of June 30, 2026, after a $805M gross public offering.

Definium Therapeutics, Inc. (DFTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dftx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights Announced positive topline results from Phase 3 Emerge study of DT120 ODT in major depressive disorder (MDD), demonstrating rapid, robu

Allergan Aesthetics, an AbbVie unit (ABBV), said the U.S. FDA accepted for review a supplemental BLA for BOTOX Cosmetic to treat masseter muscle prominence in adults. AbbVie cites two Phase 3 studies (M21-416, M21-417) meeting primary endpoints versus placebo (p=0.0046, p=0.0014) and higher patient satisfaction. If approved, it would be BOTOX Cosmetic’s fifth aesthetic indication.

AbbVie (NYSE: ABBV) said Canada’s Drug Agency (CDA-AMC) recommended UBRELVY (ubrogepant) for reimbursement with conditions for acute treatment of migraine in adults with moderate to severe pain, with or without aura. The decision cites evidence from Phase 3 ACHIEVE I and ACHIEVE II studies and aims to expand migraine-specific acute options.

Reuters reports AbbVie trimmed its 2026 adjusted EPS forecast to reflect its planned $10.9 billion acquisition of Apogee Therapeutics, agreed in June. AbbVie said the deal would reduce full-year earnings by 14 cents per share, with 10 cents offset, net 4 cents. In Q2, adjusted profit was $3.65 per share on $16.99B revenue, beating LSEG estimates; Skyrizi and Rinvoq sales rose.